BRIEF-Sanofi Says Dupixent Shows Reduction In Exacerbations In Phase 3 Trial As A Potential Treatment For COPD

Sanofi SA: * SANOFI-DUPIXENT SHOWS REDUCTION IN EXACERBATIONS IN PHASE 3 TRIAL AS A POTENTIAL TREATMENT FOR COPD

* SANOFI-PHASE 3 TRIAL OF DUPIXENT SHOWED SIGNIFICANT REDUCTION (30%) IN EXACERBATIONS COMPARED TO PLACEBO * SANOFI-PRIMARY AND ALL KEY SECONDARY ENDPOINTS WERE MET IN A PHASE 3 TRIAL EVALUATING THE INVESTIGATIONAL USE OF DUPIXENT

* SANOFI-DUPIXENT PHASE 3 TRIAL SHOWED IMPROVEMENT IN LUNG FUNCTION (160 ML IN FEV1) COMPARED TO PLACEBO (77 ML IN FEV1) * SANOFI-DUPIXENT PHASE 3 TRIAL ENROLLED PATIENTS WITH MODERATE TO SEVERE DISEASE AND EVIDENCE OF TYPE 2 INFLAMMATION

* SANOFI-DUPIXENT PHASE 3 TRIAL SHOWED SIGNIFICANT IMPROVEMENTS IN QUALITY OF LIFE AND RESPIRATORY SYMPTOMS * SANOFI-DUPIXENT PHASE 3 SAFETY RESULTS WERE GENERALLY CONSISTENT WITH THE KNOWN SAFETY PROFILE OF DUPIXENT IN ITS APPROVED INDICATIONS

* SANOFI-OVERALL RATES OF ADVERSE EVENTS WERE 77% FOR DUPIXENT AND 76% FOR PLACEBO * SANOFI-SAFETY AND EFFICACY OF DUPIXENT AND ITEPEKIMAB IN COPD HAVE NOT BEEN FULLY EVALUATED BY ANY REGULATORY AUTHORITY

* SANOFI-ADVERSE EVENTS LEADING TO DEATHS WERE BALANCED BETWEEN DUPIXENT AND PLACEBO (1.7% PLACEBO, 1.5% DUPIXENT) Source text for Eikon: Further company coverage:

(This story has not been edited by Devdiscourse staff and is auto-generated from a syndicated feed.)